201 related articles for article (PubMed ID: 29178433)
1. Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury.
Zhao D; Li S; Liao T; Wei Y; Liu M; Han F; Luo Z; Liu X; Sun Q
Am J Transplant; 2018 May; 18(5):1083-1095. PubMed ID: 29178433
[TBL] [Abstract][Full Text] [Related]
2. Triptolide Attenuates Transplant Vasculopathy Through Multiple Pathways.
Luo Z; Liao T; Zhang Y; Zheng H; Sun Q; Han F; Yang Z; Sun Q
Front Immunol; 2020; 11():612. PubMed ID: 32373115
[TBL] [Abstract][Full Text] [Related]
3. Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection.
Bouatou Y; Viglietti D; Pievani D; Louis K; Duong Van Huyen JP; Rabant M; Aubert O; Taupin JL; Glotz D; Legendre C; Loupy A; Lefaucheur C
Am J Transplant; 2019 Jul; 19(7):1972-1988. PubMed ID: 30748089
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
[TBL] [Abstract][Full Text] [Related]
5. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.
Luque S; Lúcia M; Melilli E; Lefaucheur C; Crespo M; Loupy A; Bernal-Casas D; Gomà M; Jarque M; Crespo E; Montero N; Manonelles A; Cruzado JM; Gil-Vernet S; Grinyó JM; Bestard O
Am J Transplant; 2019 Feb; 19(2):368-380. PubMed ID: 30085394
[TBL] [Abstract][Full Text] [Related]
6. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.
Li J; Basler M; Alvarez G; Brunner T; Kirk CJ; Groettrup M
Kidney Int; 2018 Mar; 93(3):670-680. PubMed ID: 29229189
[TBL] [Abstract][Full Text] [Related]
7. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
[TBL] [Abstract][Full Text] [Related]
8. In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection.
Yagisawa T; Tanaka T; Miyairi S; Tanabe K; Dvorina N; Yokoyama WM; Valujskikh A; Baldwin WM; Fairchild RL
Kidney Int; 2019 Feb; 95(2):350-362. PubMed ID: 30503624
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts.
Kohei N; Tanaka T; Tanabe K; Masumori N; Dvorina N; Valujskikh A; Baldwin WM; Fairchild RL
Kidney Int; 2016 Jun; 89(6):1293-306. PubMed ID: 27165816
[TBL] [Abstract][Full Text] [Related]
10. Circulating T follicular helper cells are a biomarker of humoral alloreactivity and predict donor-specific antibody formation after transplantation.
La Muraglia GM; Wagener ME; Ford ML; Badell IR
Am J Transplant; 2020 Jan; 20(1):75-87. PubMed ID: 31250973
[TBL] [Abstract][Full Text] [Related]
11. Blockade of IL-6/IL-6R Signaling Attenuates Acute Antibody-Mediated Rejection in a Mouse Cardiac Transplantation Model.
Ma M; Sun Q; Li X; Deng G; Zhang Y; Yang Z; Han F; Huang Z; Fang Y; Liao T; Sun Q
Front Immunol; 2021; 12():778359. PubMed ID: 34777394
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression of triptolide and its effect on skin allograft survival.
Yang SX; Gao HL; Xie SS; Zhang WR; Long ZZ
Int J Immunopharmacol; 1992 Aug; 14(6):963-9. PubMed ID: 1428369
[TBL] [Abstract][Full Text] [Related]
13. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
[TBL] [Abstract][Full Text] [Related]
14. Triptolide Reduces the Required Dose of Tacrolimus by Attenuating Inflammation, Enhancing Immunosuppression, and Increasing Donor Chimerism in a Heterotopic Hindlimb Transplantation Model.
Gu C; Liu F; Luo X; Zhou X; Yang J; Levin LS
Plast Reconstr Surg; 2016 Dec; 138(6):1243-1253. PubMed ID: 27879593
[TBL] [Abstract][Full Text] [Related]
15. Prolongation of rat intestinal allograft survival by administration of triptolide-modified donor bone marrow-derived dendritic cells.
Chen T; Xu H; Wang HQ; Zhao Y; Zhu CF; Zhang YH; Ji MJ; Hua YB; Wu WX
Transplant Proc; 2008 Dec; 40(10):3711-3. PubMed ID: 19100471
[TBL] [Abstract][Full Text] [Related]
16. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
[TBL] [Abstract][Full Text] [Related]
17. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
[TBL] [Abstract][Full Text] [Related]
18. Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts.
Everly MJ; Roberts M; Townsend R; Bray RA; Gebel HM
Am J Transplant; 2018 Sep; 18(9):2305-2313. PubMed ID: 29767445
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
[TBL] [Abstract][Full Text] [Related]
20. Absence of Activation-induced Cytidine Deaminase, a Regulator of Class Switch Recombination and Hypermutation in B Cells, Suppresses Aorta Allograft Vasculopathy in Mice.
Nakanishi T; Xu X; Wynn C; Yamada T; Pan F; Erickson L; Teo H; Nakagawa T; Masunaga T; Abe J; Akamatsu M; Tamura K; Jiang H
Transplantation; 2015 Aug; 99(8):1598-605. PubMed ID: 25769064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
